CD274 and non-small cell lung carcinoma: There are three FDA approved PD-L1 immunohistochemistry assays currently used as companion diagnostics: Dako 28-8 for the use of ipilimumab/nivolumab in NSCLC; Dako 22C3 for the use of pembrolizumab with multiple solid tumours; and Ventana SP142 for the use of atezolizumab with NSCLC, urothelial malignancies and triple-negative breast cancer32.